$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
多吉美治疗分化型甲状腺癌的分析
2025-10-19 11:44:20
Check Details
甲状腺癌患者吃多吉美多久才可以停药?
2025-10-19 11:44:20
Check Details
FDA批准多吉美用于晚期分化型甲状腺癌
2025-10-19 11:44:20
Check Details
多吉美对分化型甲状腺癌有效果吗?
2025-10-19 11:44:20
Check Details
塞尔帕替尼治疗RET融合阳性甲状腺癌的疗效分析
2025-10-19 11:44:20
Check Details
甲状腺癌靶向药多吉美(索拉非尼)图片及药品介绍
2025-10-19 11:44:20
Check Details
RET靶向药塞尔帕替尼图片及药品介绍
2025-10-19 11:44:20
Check Details
靶向药多吉美治疗甲状腺癌一个月的费用是多少?
2025-10-19 11:44:20
Check Details
塞尔帕替尼在RET阳性甲状腺癌中的作用
2025-10-19 11:44:20
Check Details
RET阳性甲状腺癌靶向药塞尔帕替尼使用说明书
2025-10-19 11:44:20
Check Details
乐伐替尼可提高甲状腺癌和肺转移患者的总生存期
2025-10-19 11:44:20
Check Details
乐伐替尼(Lenvatinib)纳入医保了吗?乐伐替尼(Lenvatinib)2021年最新价格
2025-10-19 11:44:20
Check Details
1
2
...
2531
2532
2533
2534
2535
2536
2537
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
2
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
3
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
4
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
5
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
6
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
7
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
8
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
9
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
10
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
11
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
12
Vemurafenib (Zelboraf) Complete Medication Guide